ArticleActa diabetologica2017
Joint modeling of longitudinal autoantibody patterns and progression to type 1 diabetes: results from the TEDDY study.
Article in Acta diabetologica, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Single-cell RNA sequencing in studies of type 1 diabetes mellitus: modern state-of-the-art and technical peculiarities.Frontiers in endocrinology · 2025Review
- Time to reframe the disease staging system for type 1 diabetes.The lancet. Diabetes & endocrinology · 2024Review
- Data-Driven Phenotyping of Presymptomatic Type 1 Diabetes Using Longitudinal Autoantibody Profiles.Diabetes care · 2024Article
- Network Cluster Analysis of PPI and Phenotype Ontology for Type 1 Diabetes Mellitus.Iranian journal of biotechnology · 2024Article
- Refining the Definition of Stage 1 Type 1 Diabetes: An Ontology-Driven Analysis of the Heterogeneity of Multiple Islet Autoimmunity.Diabetes care · 2023Article
- Consortium-based approach to receiving an EMA qualification opinion on the use of islet autoantibodies as enrichment biomarkers in type 1 diabetes clinical studies.Diabetologia · 2023Review
- Stratifying risk for onset of type 1 diabetes using islet autoantibody trajectory clustering.Diabetologia · 2023Article
- Quantifying the utility of islet autoantibody levels in the prediction of type 1 diabetes in children.Diabetologia · 2023Article
- Islet Autoantibody Levels Differentiate Progression Trajectories in Individuals With Presymptomatic Type 1 Diabetes.Diabetes · 2022Article
- Islet Autoantibody Type-Specific Titer Thresholds Improve Stratification of Risk of Progression to Type 1 Diabetes in Children.Diabetes care · 2022Article
- Zinc transporter 8 (ZnT8) autoantibody prevalence in black South African participants with type 1 diabetes.BMC endocrine disorders · 2021Article
- The Multifactorial Progression from the Islet Autoimmunity to Type 1 Diabetes in Children.International journal of molecular sciences · 2021Review
- Bayesian joint modelling of longitudinal and time to event data: a methodological review.BMC medical research methodology · 2020Review
- Predicting Type 1 Diabetes Onset using Novel Survival Analysis with Biomarker Ontology.AMIA ... Annual Symposium proceedings. AMIA Symposium · 2020Article
- Progression from islet autoimmunity to clinical type 1 diabetes is influenced by genetic factors: results from the prospective TEDDY study.Journal of medical genetics · 2019Article
- A Joint Modeling Approach for Childhood Meat, Fish and Egg Consumption and the Risk of Advanced Islet Autoimmunity.Scientific reports · 2019Article
- Article
- The Environmental Determinants of Diabetes in the Young (TEDDY) Study: 2018 Update.Current diabetes reports · 2018Review
- The Impact of Pancreatic Beta Cell Heterogeneity on Type 1 Diabetes Pathogenesis.Current diabetes reports · 2018Review
- Dynamics of Plasma Lipidome in Progression to Islet Autoimmunity and Type 1 Diabetes - Type 1 Diabetes Prediction and Prevention Study (DIPP).Scientific reports · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
aimsThe onset of clinical type 1 diabetes (T1D) is preceded by the occurrence of disease-specific autoantibodies. The level of autoantibody titers is known to be associated with progression time from the first emergence of autoantibodies to the onset of clinical symptoms, but detailed analyses of this complex relationship are lacking. We aimed to fill this gap by applying advanced statistical models.
methodsWe investigated data of 613 children from the prospective TEDDY study who were persistent positive for IAA, GADA and/or IA2A autoantibodies. We used a novel approach of Bayesian joint modeling of longitudinal and survival data to assess the potentially time- and covariate-dependent association between the longitudinal autoantibody titers and progression time to T1D.
resultsFor all autoantibodies we observed a positive association between the titers and the T1D progression risk. This association was estimated as time-constant for IA2A, but decreased over time for IAA and GADA. For example the hazard ratio [95% credibility interval] for IAA (per transformed unit) was 3.38 [2.66, 4.38] at 6 months after seroconversion, and 2.02 [1.55, 2.68] at 36 months after seroconversion.
conclusionsThese findings indicate that T1D progression risk stratification based on autoantibody titers should focus on time points early after seroconversion. Joint modeling techniques allow for new insights into these associations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.